Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27579143 | 0.88 | GAA (0.60) | MAPTGAAALDH1A1HPGDHSD17B10 | |
| SCHEMBL7432280 | 0.85 | MAPT (0.44) | MAPTGAACA9MEN1KMT2A | |
| SCHEMBL10855641 | 0.81 | GAA (0.44) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL17413603 | 0.81 | GAA (0.64) | MAPTGAATHRB | |
| SCHEMBL27930597 | 0.79 | GAA (0.62) | MAPTGAA | |
| SCHEMBL19066011 | 0.79 | GAA (0.62) | MAPTGAA | |
| SCHEMBL4999499 | 0.79 | GAA (0.62) | MAPTGAAKDM4EALDH1A1 | |
| SCHEMBL27732139 | 0.79 | GAA (0.62) | MAPTGAAMEN1KMT2ATDP1 | |
| SCHEMBL16140165 | 0.77 | TNF (0.41) | MAPTGAAMEN1KMT2AKDM4E | |
| SCHEMBL31370222 | 0.77 | EGLN1 (0.44) | MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MAPT 3993/4885GAA 141/4885CA9 1217/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | MAPT 3993/4885GAA 141/4885CA9 1217/4885 |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MAPT 3993/4885GAA 141/4885CA9 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.